TNFalfa Blocking Treatment of Spondylarthropathies
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of the study is to establish a Danish cohort of spondylarthropathy (SpA) patients who are being treated with TNFalfa blockers. By following the TNFalfa blocking treated patients the researchers want to identify better biomarkers for disease activity and disease progression. In addition, the researchers want to identify predictors for disease progression.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Age>18 years old
Spondylarthropathies according to the European Spondylarthropathy Study Group (ESSG) criteria
Sacroiliitis by X-ray or magnetic resonance imaging (MRI)
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)>3
No signs of tuberculosis (TB)
Wish of pregnancy or nursing
Previous treatment with TNFalfa blocker
Disease-modifying anti-rheumatic drugs (DMARDs) other than methotrexate (MTX) later than 4 weeks before inclusion
Steroid treatment later than 4 weeks before inclusion
Immunosuppressing agents later than 4 weeks before inclusion
Severe infections within 3 months
Active hepatitis B and C
Active or latent TB
Severe chronic diseases
Heart insufficiency (New York Heart Association [NYHA] 3 and 4)
Systemic lupus erythematosus (SLE) or SLE-like disease